Bivalirudin Needs Closer Look in ACS, Study Suggests

EuroPCR 2013 — PARIS — Whether clinicians chose bivalirudin (Angiomax) or heparin as monotherapy made no difference in outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing PCI, a registry study showed.


< Back to Listings